Clavis Pharma Announces Positive Elacytarabine Phase II Results

Independent data monitoring committee confirms initial results

19-Mar-2009 - Norway

Clavis Pharma ASA announced positive results from a second interim analysis of the elacytarabine (CP-4055). Phase II study in patients with late stage acute myeloid leukaemia (AML). An interim analysis of data from 40 patients has been assessed by an independent data monitoring committee. The review confirms the positive results from the first 20 patients presented earlier.

Late stage AML patients represent a difficult-to-treat patient group that have failed two previous therapeutic regimens. As part of the Phase II study, these patients received their third line treatment, also called second salvage therapy. The treatment of this patient group constitutes a significant unmet medical need, as there is currently no standard therapy available and expected survival is very short. The interim data from the Phase II study shows that six out of 40 patients attained complete response, which is higher than comparable published data for this patient group. Elacytarabine was well tolerated, also by elderly patients. The study is still ongoing.

Preliminary interim data from the Phase II study were previously announced at the American Society of Hematology Annual Meeting in December 2008. Elacytarabine is currently in development in AML both as monotherapy for late stage patients and in combination with idarubicin for patients who have failed early therapy (1st course failures). Elacytarabine has a favourable safety profile and clinical responses have been reported throughout the Phase I and II parts of the program. A Phase I study in combination with idarubicin is completed, and a Phase II combination study in patients who have failed early therapy is under planning. The current elacytarabine AML program involves 15 major cancer centres in the USA and Europe.

Elacytarabine has previously been granted orphan drug designation by both the FDA and the European Commission for the treatment of AML. Elacytarabine is proposed by the World Health Organization as the international non-proprietary name (pINN) for CP-4055. The proposal is supported by the United States Adopted Name Council.

https://www.bionity.com/en/news/98507/clavis-pharma-announces-positive-elacytarabine-phase-ii-results.html